Kura Oncology, Inc. - 10-Q Filing
Kura Oncology filed its Q1 2026 10-Q report with $39.1 million in cash and cash equivalents as of March 31, 2026, down from $149.1 million at December 31, 2025. The company reported total assets of $652.6 million compared to $738.4 million previously. Total liabilities were $544.7 million versus $564.2 million in the prior quarter.
Tickers: $KURA